drugset / Trial / NCT03433196
Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases
RandomizedParallel-groupDouble-blindTreatment
Summary
To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases; To determine the safety of HS-25 (20mg) combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases
Timeline
- Start
- 2016-06-07
- Primary completion
- 2018-06-30
- Completion
- 2018-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 10 mg | Oral |
| Subject | Atorvastatin | Small molecule | 20 mg | Oral |
| Subject | HYZETIMIBE | Small molecule | 20 mg | Oral |